# Polares Medical

> Polares Medical is a clinical-stage structural-heart company developing MRace, a catheter-delivered implant that restores the posterior leaflet of a leaking mitral valve rather than clipping the leaflets together or replacing the entire valve. Headquartered in Lausanne with a Palo Alto operation, the company is testing the investigational device across international studies and raised a $50 million Series C announced in March 2026 after reporting experience in more than 70 patients.

- **Founded:** 2010
- **Headquarters:** Lausanne, Switzerland
- **Founders:** Jacques Essinger (Co-founder, CEO and Chairman), Alex Khairkhahan (Co-founder, COO and CTO)
- **Products:** MRace Transcatheter Leaflet Restoration system
- **Notable:** Established posterior-leaflet restoration as a distinct approach between transcatheter repair and full mitral-valve replacement., Reported clinical experience in more than 70 patients by March 2026., Reported encouraging one-year safety and efficacy data in its Series C announcement.

## Products & services

- **MRace Transcatheter Leaflet Restoration system** — An investigational, catheter-delivered posterior-leaflet restoration system using a five-anchor nitinol frame and an Adaptive Coaptation Element made from bovine pericardium. It is designed to reduce functional mitral regurgitation while avoiding left-ventricular outflow obstruction and preserving later treatment options.

## Achievements

- Established posterior-leaflet restoration as a distinct approach between transcatheter repair and full mitral-valve replacement.
- Reported clinical experience in more than 70 patients by March 2026.
- Reported encouraging one-year safety and efficacy data in its Series C announcement.
- Raised approximately $115 million across three disclosed rounds from 2018 through 2026.
- Advanced clinical programs in the United States, Europe, Australia and Brazil.

## Latest updates

- **2026-09** — Polares was announced as a sponsor and presenter for the Georgian MedTech Innovation Summit, with plans to present MRace technology and clinical experience.
- **2026-06** — A new U.S. early-feasibility study of the MRace implant was listed with a planned 2026 enrollment period.
- **2026-03** — The company announced a $50 million Series C to expand U.S. development and advance studies in the United States, Europe and Australia.
- **2025-10** — Polares presented MRace at the TCT 2025 structural-heart meeting.
- **2025-05** — MRace design, concept and clinical experience were presented at EuroPCR 2025.

## Links

- Website: https://www.polaresmedical.com/
- LinkedIn: https://www.linkedin.com/company/polares-medical/

---

Profile page: https://yespress.io/polares-medical
Published by YesPress — https://yespress.io
Last updated: 2026-09-28